The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Venetoclax in combination with low-dose cytarabine – a promising regimen for the treatment of AML
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from the Monash University, Victoria, Australia, discusses the potential use of venetoclax in combination with low-dose cytarabine for the treatment of acute myeloid leukemia (AML) in elderly patients, at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain. He tells us about the impressive results of a Phase I/II clinical trial on the administration of this combination regimen on 61 patients, namely producing high remission rates (NCT02287233). The identification of certain cytogenetic characteristics that may be predictive of an even higher clinical response rate in patients, is also discussed here. He hopes that this new combinatorial regimen may become the future standard of care and a Phase III trial has already commenced.
